Introduction
Hodgkin lymphoma (HL) is one of the most frequent lymphomas in the Western world, with an annual incidence of about 3 cases per 100,000 persons. This lymphoid malignancy involves peripheral lymph nodes and can also affect organs such as liver, lung, and bone marrow. About 40% of patients suffer from constitutional symptoms ("B-symptoms"). Based on differences in the histological picture and the phenotype of the tumor cells, HL is subclassified into nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted, and nodular lymphocyte-predominant HL (NLPHL) (1) . The first four subtypes are collectively called classical HL. The tumor cells of HL are very rare and usually account for only about 0.1%-2% of cells in the tissue (Figure 1 ). In classical HL, the malignant cells are referred to as Hodgkin and Reed-Sternberg (HRS) cells, and in NLPHL they are lymphocyte-predominant (LP) cells (1) . These malignant cells are large, and in classical HL one may distinguish mononucleated Hodgkin cells and bi-or multinucleated Reed-Sternberg cells. In classical HL, the tumor cells are infected by EBV in about 40% of cases, which is of pathogenetic relevance.
Cellular origin of HRS and LP cells
Tumor cells usually retain key phenotypic features of the normal cells from which they originate. Therefore, the expression of various B cell markers by LP cells indicates their B cell derivation (2) . Moreover, LP cells express markers typical for GC B cells, including BCL6, the key regulator of the GC B cell program (3, 4) . GC B cells are antigen-activated mature B cells involved in T cell-dependent immune responses. A close relationship of LP cells to GC B cells is also indicated by the histology of NLPHL, in which LP cells grow in GC-like structures in association with follicular dendritic and follicular Th cells (1) . The B cell derivation of LP cells and their monoclonality was proven by the detection of clonal Ig heavy-and light-chain variable (V) gene rearrangements in these cells (5, 6) . The Ig V genes of LP cells carry somatic mutations, which are introduced during the GC reaction and hence are a hallmark of GC and post-GC B cells (5, 6) . Several cases showed intraclonal diversity as a sign of ongoing hypermutation during clonal expansion (5, 6) , further validating the GC B cell origin of LP cells. LP cells seem to be selected for expression of a functional B cell receptor (BCR) (7) .
Previous immunophenotypic studies have not revealed the origin of HRS cells because they show a very unusual phenotype, with coexpression of markers for various hematopoietic lineages. HRS cells can express markers of T cells (CD3, NOTCH1, GATA3), cytotoxic cells (granzyme B, perforin), B cells (Pax5, CD20), dendritic cells (fascin, CCL17), NK cells (ID2), myeloid cells (CSFR1), and granulocytes (CD15) (3) . HRS cells always express the activation marker CD30 (1) .
The origin of HRS cells from mature B cells was clarified by the demonstration that they carry clonal and somatically mutated Ig heavy-and light-chain gene rearrangements (8) (9) (10) (11) . Surprisingly, about 25% of classical HL cases showed loss of function Ig gene mutations, including nonsense mutations, in their V genes (8) (9) (10) (11) . GC B cells acquiring such mutations normally rapidly undergo apoptosis. Thus, critical steps in HL pathogenesis most likely happen in the GC to enable the crippled HRS cell precursors to escape apoptosis. As many other unfavorable mutations are not easily identifiable, HRS cells as a rule may derive from GC B cells with unfavorable Ig gene mutations, and hence from apoptosis-prone GC B cells (9) . It should, however, be stressed that HL development (like tumor development in general) is a multistep process, so that some transforming events might be carried by HRS precursor cells before they enter the GC reaction, and final transforming events might occur after the cells have left the GC.
Because of the expression of T cell markers by HRS cells in a fraction of classical HL, several such cases were studied for a potential T cell derivation, and some of them indeed turned out to carry T cell receptor gene rearrangements (12, 13) . Thus, in rare instances lymphomas diagnosed as HL have a T cell origin and represent rare variants of classical HL.
A recent study reported the detection of putative HRS stem cells among CD20 + BCR + CD30 -B cells in the peripheral blood and lymph nodes of patients with HL (18) . However, that work was criticized based on technical concerns, as no clear evidence was provided for a clonal relationship between the HRS cells and their putative stem cells (19) , and further studies are needed to clarify this issue. Further complicating the question was the detection of side population (SP) cells in several HL cell lines (20, 21) . SP cells are defined by negativity for Hoechst dye 33342 staining, due to expression of ABC transporters, which expel the dye from the cell (22) . As such transporters also export various chemotherapeutic drugs, SP cells are often chemoresistant. Moreover, these cells share features with cancer stem cells (22) . The rare SP cells in HL cell lines (about 0.5% of the HRS cells) were found among the mononuclear Hodgkin cells, were CD30 + and CD20 -, showed chemoresistance, and could reestablish HRS cell clones upon subcloning (20, 21) . However, SP cells were not detected in all HL cell lines (20, 21) , which argues against a general role of these cells in the maintenance of HRS cell clones.
The lost B cell phenotype of HRS cells
Although HRS cells derive from mature B cells, they show a global downregulation of the B cell gene expression program (23) (24) (25) , which is unique among B cell lymphomas in its extent. The initial event that causes this extensive reprogramming is unknown, but several contributing factors have been identified. HRS cells downregulate expression of numerous B cell transcription factors, such as OCT2, PU.1, and BOB1, likely causing downregulation of their respective target genes (24, 26) . B cell-specific genes are also silenced by epigenetic mechanisms in HL (27, 28) . Furthermore, HRS cells aberrantly express master regulators of other hematopoietic cell lineages that suppress B cell genes, in particular the T cell factor Notch1 and the NK cell factor ID2 (29) (30) (31) . ID2, as well as activated B cell factor 1, which is also highly expressed in HRS cells, directly inhibit the important B cell transcription factor E2A (30) (31) (32) . The transcription factors STAT5A and STAT5B are also involved in the downregulation of B cell genes in HRS cells (33) .
Expression of multiple key transcription factors of HSCs may further contribute to the peculiar phenotype of HRS cells. HRS cells express multiple members of the polycomb group family 1 and 2 complexes (34-36); although some of these are expressed in normal B cells, their co-expression is not seen in normal B cells. As polycomb group factors can downregulate B cell genes, and as HSC and lymphoid progenitors show promiscuous coexpression of markers of distinct hematopoietic cell types (37) (38) (39) , these factors may play a role in the downregulation of B cell genes and the expression of markers of other lineages in HRS cells.
Transforming events that are as yet unknown may contribute to the consistent downregulation of the B cell program in HRS cells. Moreover, this specific feature may be directly linked to the fact that HRS cells are derived from pre-apoptotic GC B cells. It is also possible that, for GC B cells with low-affinity BCRs or complete loss of BCR expression, the strong selection pressure to undergo apoptosis may select for loss of the B cell identity, so that these "failed" B cells escape the apoptosis (23) .
Role of EBV in HL pathogenesis
In about 40% of classical HL in the Western world, and in more than 90% of pediatric cases of HL in Central America, HRS cells are latently infected by EBV, a γ-herpes virus (40) . HRS cells are clonally infected, suggesting that EBV infection is an early event in HL pathogenesis (41) . EBV has several types of latency, and in HRS cells latency II is observed, meaning that EBV-encoded genes EBV nuclear antigen 1 (EBNA1), latent membrane protein 1 (LMP1), and LMP2a are expressed. EBNA1 is essential for the replication of the episomal EBV genome in proliferating cells. LMP1 mimics an active CD40 receptor, a central costimulatory molecule for B cells (42) . LMP2a carries a cytoplasmic motif that resembles the signaling module of the BCR. As CD40 and BCR signaling are main regulators of survival and selection of GC B cells, it was speculated that LMP1 and LMP2a can rescue BCR-deficient B cells from apop- tosis by replacing these signals (43) . Indeed, EBV-immortalized B cell lines can be established from BCR-deficient GC B cells (44, 45) . This suggests that EBV might play a major role as an initial event in HL pathogenesis by rescuing crippled GC B cells from apoptosis. Interestingly, all HL with null BCR mutations are EBV positive, strongly supporting an essential role of EBV in the pathogenesis of such lymphomas (46) . However, the function of LMP2a in the established HRS cell clone is uncertain because most components of BCR signaling are downregulated.
Somatic genetic lesions and germline alterations
HRS cells usually show multiple chromosomal abnormalities and are aneuploid (47) . In addition to clonal abnormalities, multiple subclonal aberrations are found, indicating chromosomal instability of the tumor (47) . Chromosomal translocations involving the Ig loci, a hallmark of many B cell non-Hodgkin lymphomas, were detected in about 20% of classical HLs (48) . Some of them involve the known oncogenes BCL1, BCL2, BCL3, BCL6, REL, and MYC, but for most cases the partner genes are unknown (48, 49) . Considering the general silencing of the Ig loci in HRS cells, it is intriguing to ask whether oncogenes linked to the Ig loci through translocations show deregulated expression in the established HRS cell clone. Alternatively, these translocations might be important during early stages of HL development, when the HRS precursor cells still have a B cell phenotype, but become irrelevant later when additional transforming events are acquired.
The detection of constitutive activity of the transcription factor NF-κB in HRS cells (50) prompted numerous studies to search for gene mutations that contribute to this activity ( Figure 2 ). Genomic gains of REL, encoding an NF-κB factor, are present in about 30% of cases (51, 52) . The positive regulator of the alternative NF-κB pathway, NIK, is also frequently affected by genomic gains in HRS cells (53, 54) . Mutations in the genes of the NF-κB inhibitors IκBα and IκBε were found in about 10%-20% of cases (55) (56) (57) (58) . A20, which is encoded by the TNFAIP3 gene, and which is an inhibitor of NF-κB activity, is
Figure 2
NF-κB and JAK/STAT activity in HRS cells. In the canonical NF-κB signaling pathway, stimulation of various receptors, which complex with TNF receptor-associated factors (TRAFs) and the receptor interacting protein (RIP), leads to activation of the IKK complex, targeting the NF-κB inhibitors IκBα and IκB for ubiquitination and proteasomal degradation. As a consequence, the NF-κB transcription factors translocate into the nucleus, where they activate multiple genes. TNFAIP3 and CYLD are further negative regulators of NF-κB signaling. In the alternative NF-κB pathway, activation of receptors such as CD40 and TACI causes stimulation of the kinase NIK (MAP3K14), which then activates an IKKα complex. NIK activity is negatively regulated by TRAF3. Activated IKKα processes p100 to p52, which translocates as p52/RELB heterodimers into the nucleus. HRS cells have constitutive activity of both NF-κB pathways. Activation of CD40, RANK, BCMA, and TACI through ligands expressed on lymphoma-infiltrating cells likely contributes to this activity. Numerous genetic lesions and signaling through the EBV-encoded latent membrane protein 1 in EBV-positive cases of HL play important roles in the deregulated NF-κB activity. The JAK/STAT pathway is the main signaling pathway for cytokines. In HRS cells, STAT3, -5, and -6 are constitutively active. In addition to activation of cytokine receptors, such as the IL-13 receptor and the IL-21 receptor, activation of this pathway is mediated by genomic gains or translocations of the JAK2 gene and frequent inactivating mutations of the SOCS1 gene. The frequency of genetic lesions and viral infections affecting NF-κB or STAT activity in HRS cells is indicated as percentages. Adapted with permission from Nature Reviews Cancer (2) . inactivated in about 40% of classical HL cases (59, 60) . Notably, most TNFAIP3-mutated HLs are EBV negative, suggesting that A20 inactivation and EBV infection are largely mutually exclusive transforming events in classical HL (60) . TNFAIP3 reconstitution in A20-deficient HL cell lines impairs survival of the cells, establishing TNFAIP3 as a tumor suppressor gene (60) . Other regulators of NF-κB, i.e., BCL3 and the tumor suppressor genes CYLD and TRAF3 are rarely mutated in HRS cells (53, 61, 62) . Hence, multiple genetic lesions in the NF-κB pathway contribute to its dysregulation in HRS cells. Remarkably, HL cell lines often carry mutations of several NF-κB regulators, indicating that HRS cells may require distortions of more than one factor of this pathway to obtain the strong NF-κB activity that is essential for their survival and proliferation.
Another signaling pathway activated in HRS cells for which genetic lesions have been found is the JAK/STAT pathway ( Figure  2 ). JAK2 shows chromosomal gains in about 20% of HL, and in rare cases is translocated (63, 64) . JAK2 functions in HRS cells as an activator of STAT signaling and is also involved in epigenetic regulation, as it can phosphorylate histone H3 (65) . SOCS1, a main inhibitor of STAT activity, is affected by inactivating mutations in about 40% of classical HL cases (66) .
The genomic region on chromosome 9p24, which shows gains in HRS cells and in which the JAK2 gene is located, also encompasses the gene JMJD2C and the programmed death 1 ligand (PD-1L) genes PD-L1 and PD-L2 (65, 67) . PD-1Ls can inhibit PD-1-expressing T cells and thereby may contribute to an immunosuppressive microenvironment in HL (67) . JMJD2C encodes a histone demethylase, and downregulation of its expression in HL cell lines is toxic (65) . Thus, a single genetic event -gains of chromosomal region 9p24 -may contribute to HL pathogenesis by the concurrent deregulation of at least four genes.
Translocations involving the MHC class II transactivator gene CIITA have been detected in about 15% of classical HL cases (68) . These translocations seem to impair CIITA function and hence dampen MHC class II expression. Downregulation of MHC class II expression by HRS cells is an adverse prognostic factor (69), but the reasons for this association are unclear. Other genes that were examined for mutations in HRS cells, including TP53, CD95, and ATM, were only rarely mutated (3) .
By comparison, little is known about genetic lesions in LP cells. Translocations of the BCL6 protooncogene are found in about 30% of NLPHL cases (70) . SOCS1 is inactivated in LP cells by somatic mutations in 40% of cases (71) . Although LP cells show strong NF-κB activity (72) , genetic lesions of TNFAIP3 and NFKBIA are rare, if they occur at all, in these cells (73) . As LP cells also appear to lack REL gains and are not infected with EBV (40), the mechanisms for NF-κB activation in HRS and LP cells seem to be strikingly different.
Several recent studies addressed the issue of whether germline alterations or polymorphisms contribute to HL pathogenesis; indeed, HL is one of the lymphomas with the strongest familial association (74) . KLHDC8B was found as a constitutional translocation partner in the germline of a family with several HL patients (75) . Moreover, a gene polymorphism causing reduced KLHDC8B translation occurs at increased frequency in other families with HL. The function of KLHDC8B is largely unknown, but its downregulation in a cell line results in increased frequency of binucleated cells (75) . In another study, a germline frameshift mutation of the NPAT gene was found in a family with four members affected by NLPHL (76) . Moreover, a replacement mutation in NPAT was observed at significantly increased frequency in sporadic NLPHL and classical HL patients than in healthy controls. The consequences of NPAT mutations in HRS cells remain to be clarified. A genome-wide association study of HL identified risk loci at 2p16.1, 8q24.21, and 10p14 (77) . Although the odds ratios are relatively low, it is remarkable that the risk loci involve REL (discussed above), PVT1 (involved in translocations in lymphoid malignancies), and GATA3 (a T cell transcription factor that shows aberrant expression and activity in HRS cells) (78) .
Deregulated signaling pathways and transcription factors
As discussed above, HRS cells show constitutive activity of the NF-κB and the JAK/STAT signaling pathways. These two pathways are usually only transiently activated in B lymphocytes. Also, as mentioned, HRS cells show constitutive activity of polycomb group proteins and of Notch1. Activation of Notch1 is mediated by its ligand Jagged1, which is expressed by cells in the HL microenvironment (79) . Moreover, HRS cells have downregulated the Notch1 inhibitor Deltex (29) .
Several additional signaling pathways show deregulated activity in HRS cells. These include the PI3K/AKT pathway and the MAPK/ERK pathway (80, 81) . Inhibition of these pathways in HL cell lines has apoptotic and/or anti-proliferative consequences (80, 81) , suggesting their critical role in HRS cell survival and proliferation. HRS cells also show aberrant expression and activity of multiple receptor tyrosine kinases that are not normally expressed by B cells (82, 83) . Receptor tyrosine kinases have multiple functions in the regulation of cell growth, survival, and differentiation. The aberrant expression of the myeloid cell receptor and protooncogene CSF1R in HRS cells is mediated through activation of an endogenous long terminal repeat located upstream of the CSF1R gene (83) .
Deregulated microRNA expression in HRS cells
MicroRNAs (miRNAs) are small, non-coding RNAs that bind to complementary sequences in the 3′ end of mRNAs and have multiple important physiological functions. Binding of a miRNA to an mRNA induces either degradation of the mRNA or translational silencing. Molecular studies have revealed a number of miRNAs with deregulated expression in HRS cells as compared with normal B cells (84, 85) . For most of these, it is unclear whether their deregulated expression is of pathophysiological relevance. However, the diminished expression of miR135a appears to contribute to high expression of its target gene JAK2 (86) , and the increased expression of members of the miR17/106b seed family negatively regulates p21, an inhibitor of cell cycle progression (87) . Moreover, miR155, which is highly expressed in HRS cells, has oncogenic properties in B lineage cells (88) , pointing to a pathogenic role.
Microenvironmental interactions
The microenvironment that surrounds the malignant cells of HL is a critical determinant of its initiation and progression. HRS cells interact with CD4 + and CD8 + T cells, B cells, plasma cells, macrophages, mast cells, dendritic cells, neutrophils, eosinophils, and fibroblasts and indeed actively attract them via the secretion of cytokines and chemokines (Figure 3) . The microenvironment in HL is unique among lymphomas both in the complexity of cell types involved and its size, with the non-tumor cells often accounting for 99% of cells in the tumor.
The attraction of many of these cells and their interaction with HRS cells is presumably a very important factor for the survival and proliferation of HRS cells. Indeed, HRS cells are usually not found in the peripheral blood, and it is very difficult to grow HRS cells in culture or in immunodeficient mice (89, 90) . Numerous interactions can be envisioned. For example, CD4 + Th cells, which are often in close contact with HRS cells, express CD40L and CD28, the ligands for CD40 and CD80/CD86, which are expressed by HRS cells (91, 92) . CD40 stimulation leads to NF-κB activation, and signaling through CD80 is an important costimulatory signal in B cell-T cell interaction. Other factors and interactions help to rescue HRS cells from an immunological attack, including inhibition of cytotoxic T cells by Tregs (93) . Cytotoxic T cells are also inhibited through expression of the PD1 and CD95 ligands and secretion of IL-10, TGF-β, and galectin1 by the HRS cells (94) (95) (96) (97) .
Current and developing treatment options
With the introduction of multi-agent chemotherapy and improved radiation techniques, the prognosis of patients with HL has substantially improved. Depending on stage and clinical risk factors, 65%-90% of patients can be rendered diseasefree after five years (98) . Patients are usually divided into early favorable, early unfavorable, and advanced-stage risk groups. For early favorable patients with classical HL, two cycles of ABVD chemotherapy followed by involved field radiotherapy (IFRT) with 20 Gy are considered standard of care (99) . Early unfavorable patients usually receive four cycles of ABVD chemotherapy followed by IFRT with 30 Gy (100, 101). Treatment of patients with advanced-stage HL is more controversial: six to eight cycles of ABVD have been regarded standard of care for many years (102, 103) , but this regimen is being challenged by the more effective but also more toxic BEACOPP escalated approach (99) . Direct comparisons between ABVD and BEA-COPP escalated confirmed that better tumor control is achieved with BEACOPP escalated but failed to prove differences in overall survival due to the low number of patients included (104, 105) . The HD15 trial of the German Hodgkin Study Group (GHSG) demonstrated that six cycles of BEACOPP escalated are less toxic and more effective than the old standard of eight cycles and thus represent the new GHSG standard of care (106) . In stage IA NLPHL, patients are usually treated with IFRT alone, whereas classical HL is treated with combined modality. All other NLPHL patients receive the same treatment as those with classical HL (107) . In addition, anti-CD20 monoclonal antibodies have been shown to be effective when used as single agents in relapsed NLPHL patients (108, 109) .
The current goal in the treatment of HL patients is to reduce toxicity but maintain efficacy. The rationale for attempting dose reduction is the high risk of acute and long-term toxicity including secondary neoplasia, organ toxicity to heart and lung, fatigue, and infertility (110) . Based on retrospective, nonrandomized studies, positron emission tomography is currently being explored to identify high-risk patients early in the course of chemotherapy (111, 112) .
Another approach to reduce toxicity of treatment while maintaining efficacy is the development of less toxic, targeted drugs. Here, the CD30 antigen has been a focus of interest due to the strong expression on HRS cells. Several monoclonal antibodies targeting CD30 have been evaluated in various formats (113) . Recently, a new antibody drug conjugate targeting CD30, brentuximab vedotin, demonstrated very good efficacy and tolerability in a phase I study (114) . Brentuximab vedotin was subsequently registered for the treatment of relapsed HL and CD30 + anaplastic large cell lymphoma. A number of other promising new drugs targeting pathways active in HL are currently being evaluated in clinical trials (Table 1) and might further improve the treatment of HL. 
Conclusions and perspective

